Source: Hong Kong Government special administrative region
Invest Hong Kong (InvestHK) today (April 17) hosted the “Advanced Therapy Products Opportunities in Hong Kong and Beyond” forum, gathering over 170 leading scientists, industry leaders, and regulatory authorities from around the world. The event served as a definitive platform to showcase Hong Kong’s ascending status as a world-class hub for biomedical commercialisation, specifically within the revolutionary fields of cell and gene therapy (CGT).
Delivering her welcome remarks, the Director-General of Investment Promotion of InvestHK, Ms Alpha Lau, said, “The Government is pressing ahead with the Hong Kong Centre for Medical Products Regulation and the implementation of ‘primary evaluation’ for new drug registration – a move that will shorten time-to-market for innovative drugs and devices. InvestHK, as the investment promotion agency of the Government of the Hong Kong Special Administrative Region, stands ready to provide bespoke, end-to-end support for global pioneers looking to scale their operations across Asia from this strategic base.”